Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|October 3, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-10-03-2018
- Volume 13
- Issue 10
New Capsule R&D Solution
Author(s)Pharmaceutical Technology Editors
Lonza’s Capsugel Colorista capsule R&D solution can cut overall development time and offers greater flexibility during technical color development.
Advertisement
Lonza Pharma & Biotech’s new capsule R&D solution, Capsugel Colorista, can help drug developers cut overall development time while retaining greater flexibility during the technical development stage of coloration and before commitment to a final commercial coloring decision.
The capsules contain a variety of colorants usable in major markets and are available in different sizes for a range of doses and formulations. The company offers 150 color options in Coni-Snap gelatin capsules and more than 50 color options in Vcaps Plus capsules, for hydroxypropyl methylcellulose.
“A common issue faced by drug product developers is that the color composition choice for the commercial drug product is often made after initial stability studies,” said Emmanuelle Saugues, Color Lab EMEA supervisor for Lonza, in an Aug. 31, 2018 press release. “If new colors are introduced, it may require additional studies, which can result in costly delays. To address this problem, we have developed Colorista capsules at the Capsugel Color Lab.”
Source:
Articles in this issue
about 8 years ago
Preventing Microbial Contamination of Viral Vaccines and Vectorsabout 8 years ago
Retirement for Obsolete Heavy Metals Testsabout 8 years ago
Instrument Offers Simplified Weighing Processes and Accurate Resultsabout 8 years ago
Reaction Biology and Promega Partner on Bioassay Toolabout 8 years ago
New Software Tools Enhance Real-Time Process Monitoring in Labsabout 8 years ago
Stream Bio, 2BScientific Launch New Bioimaging Probesabout 8 years ago
Lonza Announces Technology for Automated Endotoxin Testingabout 8 years ago
SGS Implements Advanced Techniques for PBMCsAdvertisement
Related to this article
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
3
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
4
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
5